טוען...
ESR1 mutations as a mechanism for acquired endocrine resistance in breast cancer
Most breast cancers are estrogen receptor α (ER)-positive (+) and are treated with endocrine therapies targeting ER activity. Despite efforts, the mechanisms of the frequent clinical resistance to these therapies remain largely unknown. Several recent parallel studies unveiled gain-of-function recur...
שמור ב:
| הוצא לאור ב: | Nat Rev Clin Oncol |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4911210/ https://ncbi.nlm.nih.gov/pubmed/26122181 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nrclinonc.2015.117 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|